Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-27 |
2024-06 |
0 |
-1.58 |
N/A |
N/A |
2024-08-15 |
2024-03 |
0 |
N/A |
N/A |
N/A |
2024-08-15 |
2024-03 |
0 |
-24.2 |
N/A |
N/A |
2024-02-28 |
2023-12 |
-5.4 |
-3.6 |
1.8 |
33.33% |
2024-02-28 |
2023-12 |
-5.4 |
N/A |
N/A |
N/A |
2023-11-28 |
2023-09 |
-5.4 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-30 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-01 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-07-31 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2022-11-30 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-29 |
Oppenheimer |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2022-03-06 |
Mintz (Steven Michael) |
Director of Issuer |
24.49K |
Acquisition or disposition in the public market |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Bison Wealth, LLC |
213.40K |
745.83K |
1.20% |
2023-06-29 |
Blackrock Inc. |
33.11K |
115.72K |
0.19% |
2023-06-29 |
Citadel Advisors Llc |
18.75K |
65.55K |
0.11% |
2023-06-29 |
Dimensional Fund Advisors LP |
17.02K |
59.47K |
0.10% |
2023-06-29 |
IEQ Capital, LLC |
16.65K |
58.19K |
0.09% |
2023-06-29 |
Advisor Partners II, LLC |
10.10K |
35.30K |
0.06% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-08-30 |
iShares Micro Cap ETF |
22.50K |
57.59K |
0.13% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
9.08K |
31.60K |
0.05% |
2023-06-29 |
EQ Advisors Trust-1290 VT Micro Cap Port |
1.56K |
5.46K |
0.01% |
2023-07-30 |
DFA U.S. Core Equity 1 Portfolio |
2.31K |
7.45K |
0.01% |
2023-07-30 |
DFA U.S. Core Equity 2 Portfolio |
1.47K |
4.72K |
0.01% |
Split |
Date |
1 : 20 |
2024-08-15 |
1 : 100 |
2020-06-04 |
1 : 7 |
2003-04-21 |